News Focus
News Focus
icon url

jon_k84

05/11/22 1:35 PM

#471204 RE: radonculous #471199

Thank you for your post, and thank you for sharing with your colleagues.

At the end of the day, all I really care about is helping people with cancer and seeing a reward for helping support the drug's development for all these years.

If experts were saying the data wasn't good, I'd eat my losses and take it on the chin. But I'm glad to see the experts are excited about the data.
icon url

Dr Bala

05/11/22 1:35 PM

#471205 RE: radonculous #471199

Thanks for your expert opinion, Doctor. For clarification, I have a doctorate in Engineering.
icon url

ATLnsider

05/11/22 2:07 PM

#471233 RE: radonculous #471199

Thanks for chiming in Doctor. I appreciate your firsthand knowledge and perspective.
icon url

Astavakra

05/11/22 2:26 PM

#471247 RE: radonculous #471199

When word gets out to other physicians they will be asking for this.


Yes, and that's why, IMO, a journal targeted to oncologists rather than the general medical community might be preferred. We want to get this information into the hands of the doctors who are going to request and use the vaccine. So, although NEJM is a prestigious almost household name, I believe that Annals of Oncology will have more impact on our target readership. I'm hoping for the Annals. Side note: the external comparator article by Pazdur, et al, appeared in AoO.
icon url

Major_Bankz

05/11/22 2:32 PM

#471251 RE: radonculous #471199

We need a competent Doctor like you to manage NWBO, not someone who can't even wear a mask to avoid Covid, u know who i'm talking about. IMO
icon url

iclight

05/11/22 3:45 PM

#471333 RE: radonculous #471199

You wouldn't want your patients to take the placebo first since those patients had a better OS outcome?

Of course it has low toxicity. But of course you know that all the trial patients were on SOC (chemo and radiation) per the trial protocol, right? So you would be giving your patients the same toxic chemo prior to putting them on DCVax.

Did you share the results of the 2018 blended data, which were better but also included the control arm in the mOS of the ITT population? Why would mOS go down when you remove the 65 control patients? Please show your math. You had to take math in med school, right?
icon url

Kam8

05/11/22 8:26 PM

#471534 RE: radonculous #471199

Thank you so much for your amazing post.
icon url

antihama

05/12/22 3:35 PM

#472209 RE: radonculous #471199

Where's Photonic5? Are you giving him to much work to do :)